Endra secures Series A funding led by a16z to address inefficiencies in building design using its AI platform.
PUBLIC · NDRAJun 01, 2026
Round Type
Series A
Ann ArborManufacturingBiotechnologyHealth CareMedicalMedical DeviceHealth Diagnostics
Investors
Andreessen Horowitz
Description
Endra has successfully raised Series A funding to enhance its AI platform aimed at improving building design processes. This round, led by a16z, is expected to facilitate faster design completion for engineers. The funding will help automate repetitive design tasks within the construction industry. With a focus on addressing outdated building software, Endra is set to make significant advancements in MEP design efficiency.
Company Information
Company
ENDRA Life Sciences
Location
Ann Arbor, Michigan, United States
About
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Fundz sees it the moment ENDRA Life Sciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Ann ArborManufacturingBiotechnologyHealth CareMedicalMedical DeviceHealth Diagnostics